Transient tissue ‘priming’ via FAK inhibition to impair pancreatic cancer progression and improve sensitivity to gemcitabine/Abraxane

通过 FAK 抑制作用的瞬时组织“启动”可损害胰腺癌进展并提高对吉西他滨/Abraxane 的敏感性

• 批准号: nhmrc : 1140125
• 负责人: Dr Paul Timpson
• 金额: $ 43.53万
• 依托单位: Garvan Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/transient-tissue-priming-sensitivity-gemcitabineabraxane/1319167
• 关键词: Transient; tissue; priming; via; FAK

The success of cancer drugs is dependent on many factors including the properties of the tumour tissue. As a tumour grows it changes the tissue around it, and this affects response to treatment. Combining classical biology with engineering to generate 3D models that mimic tumours, along with cutting-edge imaging technology and mouse models, we will target FAK-controlled cancer cell pathways that sense tissue changes, together with already approved cancer drugs to improve patient outcome.

抗癌药物的成功取决于许多因素，包括肿瘤组织的特性。随着肿瘤的生长，它会改变周围的组织，从而影响对治疗的反应。结合经典生物学和工程学，生成模拟肿瘤的3D模型，以及尖端的成像技术和小鼠模型，我们将针对fak控制的癌细胞通路，感知组织变化，以及已经批准的癌症药物，以改善患者的治疗效果。